XR Naltrexone, Sublingual BUP-NX Deemed Equally Effective

Share this content:
XR Naltrexone, Sublingual BUP-NX Deemed Equally Effective
XR Naltrexone, Sublingual BUP-NX Deemed Equally Effective

WEDNESDAY, Nov. 15, 2017 (HealthDay News) -- Although initiation of extended-release naltrexone (XR-NTX) may be more difficult, XR-NTX and sublingual buprenorphine-naloxone (BUP-NX) are equally safe and effective once initiated for opioid relapse prevention, according to a study published online Nov. 14 in The Lancet.

Joshua D. Lee, M.D., from the New York University School of Medicine in New York City, and colleagues randomized 570 opioid-dependent adults to XR-NTX (administered as monthly intramuscular injections; 283 patients) or BUP-NX (daily self-administered sublingual film; 287 patients) to examine the differences in opioid relapse-free survival.

A significant induction hurdle was seen for XR-NTX, with fewer participants successfully initiating XR-NTX versus BUP-NX (72.1 versus 94.1 percent). The researchers found that in the intent-to-treat (ITT) population, the 24-week relapse rates were greater for XR-NTX than for BUP-NX (65.4 versus 56.8 percent; hazard ratio, 1.36; 95 percent confidence interval, 1.1 to 1.68); most of the difference was due to early relapse, seen in 88.6 percent of XR-NTX induction failures. Among the treated population, the 24-week relapse rates were similar (52 versus 55.6 percent for XR-NTX and BUP-NX, respectively; hazard ratio, 0.92; 95 percent confidence interval, 0.71 to 1.18). In the ITT population, opioid-negative urine samples and opioid-abstinent days significantly favored BUP-NX, while they slightly favored XR-NTX in the as-treated population.

"In this population it is more difficult to initiate patients to XR-NTX than BUP-NX, and this negatively affected overall relapse," the authors write. "Once initiated, both medications were equally safe and effective relapse prevention. Methods to improve XR-NTX induction are needed."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »